Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 Licenses MDx Patents from Cooperative Diagnostics

NEW YORK (GenomeWeb News) – Lab21 has licensed worldwide rights to a suite of patents from Cooperative Diagnostics covering real-time PCR technology that the firm will incorporate into molecular diagnostic kits.

The Cambridge, UK-based diagnostic products and services firm said that as part of the agreement it has exclusive use of the technology on a set of biomarker targets for the oncology and infectious disease areas. Financial and other terms of the pact were not disclosed.

"The Cooperative Diagnostics technologies bring powerful new tools to our development capability including fifth-generation real-time PCR technology and we expect to launch our first CE marked companion diagnostic assays using this technology during the first half of 2012," Lab21 CEO Graham Mullis said in a statement. "These tests will be commercialized through our international distribution networks and particularly through our key global OEM partners."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.